Published online Aug 27, 2025. doi: 10.4254/wjh.v17.i8.108182
Revised: May 24, 2025
Accepted: July 23, 2025
Published online: August 27, 2025
Processing time: 142 Days and 10.3 Hours
To improve understanding of the multifaceted nature of metabolic dysfunction-associated steatotic liver disease (MASLD), the American Association for the Study of Liver Diseases, in collaboration with the European Association for the Study of the Liver and the Latin American Association for the Study of the Liver, proposed a broader and more flexible definition, highlighting the role of underlying metabolic dysfunction. MASLD represents the most common chronic liver disease worldwide; however, the impact of the disease goes beyond its epidemiological aspects. Currently, the impact on patients and healthcare syst
Core Tip: Metabolic dysfunction-associated steatotic liver disease is a complex disease with multifactorial causes. The individual's dietary pattern contributes significantly to the progression of this disease. Epigenetics, modulated by diet, is a key process helps explain the development as well as new therapeutic targets for the disease.
